


Neuraminidase-IN-11

Cat. No.:	HY-151104
CAS No.:	2685786-28-9
Molecular Formula:	C ₂₆ H ₃₄ N ₂ O ₅ S
Molecular Weight:	486.62
Target:	Influenza Virus
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Neuraminidase-IN-11 (15e) is a potent and selective neuraminidase (NA) inhibitor with the IC ₅₀ values of 4.7 nM, 8.46 nM and 1.5 nM against H1N1, H5N1 and H5N8 NAs respectively ^[1] .										
In Vitro	<p>Neuraminidase-IN-11 (15e) (0-6 μM, 40 min) has anti-NA (Neuraminidase) activity against H1N1-H274Y mutant and H5N1-H274Y mutant with the IC₅₀ values of 1.07 μM and 0.61 μM, respectively^[1].</p> <p>Neuraminidase-IN-11 (15e) (0-20 μM, 48 h) inhibits chicken embryo fibroblasts (CEFs) infected H5N1 or H5N8 with the IC₅₀ values of 4.4 μM and 0.57 μM respectively, and inhibits Madin-Darby canine kidney (MDCK) cells infected H1N1 or H3N2 with the IC₅₀ values of 0.05 μM and 12.65 μM respectively^[1].</p> <p>Neuraminidase-IN-11 (15e) has no significant inhibitory effect on the major CYP enzymes which acts on CYP1A2, CYP2C9 and CYP2C19 with the IC₅₀ values of 28.9 μM, 47.3 μM and 47.8 μM, respectively^[1].</p> <p>The metabolic stability parameters of Neuraminidase-IN-11 (15e) in human liver microsomes (HLM)^[1].</p> <table border="1" data-bbox="345 1226 881 1612"> <thead> <tr> <th>Parameters</th> <th>Neuraminidase-IN-11 (15e)</th> </tr> </thead> <tbody> <tr> <td>t_{1/2} (min)</td> <td>>145</td> </tr> <tr> <td>CL_{int(mic)} (μL/min/kg)</td> <td><9.6</td> </tr> <tr> <td>CL_{int(liver)} (mL/min/kg)</td> <td><8.6</td> </tr> <tr> <td>remaining (T = 60 min) (%)</td> <td>79.3</td> </tr> </tbody> </table> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>	Parameters	Neuraminidase-IN-11 (15e)	t _{1/2} (min)	>145	CL _{int(mic)} (μL/min/kg)	<9.6	CL _{int(liver)} (mL/min/kg)	<8.6	remaining (T = 60 min) (%)	79.3
Parameters	Neuraminidase-IN-11 (15e)										
t _{1/2} (min)	>145										
CL _{int(mic)} (μL/min/kg)	<9.6										
CL _{int(liver)} (mL/min/kg)	<8.6										
remaining (T = 60 min) (%)	79.3										
In Vivo	<p>Neuraminidase-IN-11 (15e) (oral administration, 50 mg/kg, every second day, 14 days) shows no significant change in body weight and no other toxic side effects in kunming mice^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" data-bbox="345 1829 1515 1944"> <tr> <td>Animal Model:</td> <td>Male Sprague-Dawley rat^[1]</td> </tr> <tr> <td>Dosage:</td> <td></td> </tr> </table>	Animal Model:	Male Sprague-Dawley rat ^[1]	Dosage:							
Animal Model:	Male Sprague-Dawley rat ^[1]										
Dosage:											

Administration:	2 mg/kg, i.v.; 20 mg/kg, p.o.		
Result:	The pharmacokinetic parameters of Neuraminidase-IN-11 (15e)		
	Parameters	15e (i.v.)	15e (p.o.)
	t _{1/2} (h)	0.213	0.863
	T _{max} (h)	0.083	0.5
	C _{max} (ng/mL)	7195	491
	Vd _{ss} (mL/kg)	179	-
	CL	17.2	-
	F (%)	-	1.58

REFERENCES

[1]. Han Ju, et al. Iterative Optimization and Structure-Activity Relationship Studies of Oseltamivir Amino Derivatives as Potent and Selective Neuraminidase Inhibitors via Targeting 150-Cavity. J Med Chem. 2022 Aug 8.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA